国新健康(000503) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 was ¥52,143,726.47, representing a 6.07% increase year-over-year, while total revenue for the year-to-date reached ¥134,546,259.88, up 32.18% compared to the same period last year[5]. - The net profit attributable to shareholders for Q3 2022 was -¥44,553,621.74, a decrease of 40.25% year-over-year, with a year-to-date net profit of -¥116,514,666.36, reflecting an 8.49% increase compared to the previous year[5]. - The company reported a basic earnings per share of -¥0.0491 for Q3 2022, down 39.12% year-over-year, and a diluted earnings per share of -¥0.0491, also down 39.12%[5]. - Total operating revenue for Q3 2022 reached ¥134,546,259.88, an increase of 32.2% compared to ¥101,789,615.66 in the same period last year[31]. - The net loss for Q3 2022 was ¥116,709,439.54, slightly improved from a loss of ¥127,102,873.73 in Q3 2021[31]. - The total profit (loss) for the period was -115,362,959.78, compared to -127,578,122.71 in the previous period, showing an improvement[33]. - The net profit (loss) attributable to shareholders of the parent company was -116,514,666.36, compared to -127,324,268.01 in the previous period[33]. - The total comprehensive income attributable to the parent company was -110,432,919.40, compared to -129,962,216.67 in the previous period[33]. - The basic and diluted earnings per share were both -0.1284, an improvement from -0.1417 in the previous period[33]. Expenses and Costs - Research and development expenses increased by 78.69% year-over-year to ¥37,280,844.39, indicating a significant investment in new products and technologies[10]. - Total operating costs for Q3 2022 were ¥268,392,665.84, up 15.3% from ¥232,718,054.41 in Q3 2021[31]. - Research and development expenses for Q3 2022 were ¥7,998,222.46, down 36.5% from ¥12,621,987.78 in the previous year[31]. - The company reported a credit impairment loss of ¥17,577,957.16, compared to a gain of ¥1,582,030.19 in the same period last year[31]. - The company reported a 600.40% increase in financial expenses to ¥131,924.79, primarily due to exchange rate fluctuations and reduced interest income[10]. Assets and Liabilities - The total assets at the end of Q3 2022 were ¥1,009,035,413.20, a decrease of 15.37% from the end of the previous year[5]. - The company's cash flow from operating activities showed a net outflow of -¥190,712,362.62 year-to-date, a decline of 28.79% compared to the same period last year[5]. - Cash and cash equivalents decreased to ¥151,724,911.90 from ¥352,886,146.28 at the beginning of the year, a decline of 57.0%[24]. - Total current assets as of September 30, 2022, were ¥683,988,218.47, down 22.0% from ¥877,200,636.09 at the start of the year[24]. - Total liabilities decreased to ¥327,241,510.48 from ¥405,082,955.22, a reduction of 19.2%[27]. - The company's equity attributable to shareholders decreased to ¥680,165,861.84 from ¥785,613,339.24, a decline of 13.4%[27]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 60,771[15]. - The largest shareholder, China Oceanwide Holdings Group Co., Ltd., holds 25.98% of shares, totaling 235,702,593 shares[15]. - The company has not disclosed any related party relationships among the top ten shareholders[15]. - The top ten shareholders do not include any parties that are considered acting in concert under the relevant regulations[15]. - The company has not reported any preferred shareholders or their holdings[18]. Investments and Future Plans - The company has invested 12 million RMB in Zhongzi Medical Emergency Guarantee Platform Co., Ltd., increasing its ownership to 8%[18]. - The company has paid the first installment of 6 million RMB for the investment in Zhongzi Medical[18]. - The company plans to raise up to 794.48 million RMB through a non-public offering of A-shares for various projects[21]. - The company plans to focus on market expansion and new product development in the upcoming quarters[29]. Organizational Changes - The organizational structure of the company has been adjusted to enhance operational efficiency[19]. - The company has changed its registered address to Qingdao, Shandong Province[20].